Tocilizumab for juvenile Takayasu arteritis complicated with acute heart failure at onset

Keita Kanamori(National Center For Child Health and Development), Shuichi Ito(Yokohama City University), Masao Ogura(Hokkaido University Hospital), Akira Ishiguro(National Center For Child Health and Development), Kenji Ishikura(Kitasato University)

Modern Rheumatology Case Reports

December 14, 2021

10.1093/mrcr/rxab036

Cited by 2

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial

|The Lancet|2014|450

IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome

|Pediatric Nephrology|2022|278

Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease

|Clinical and Experimental Nephrology|2013|267

Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies

|Pediatric Nephrology|2021|149

A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment

|Kidney International|2014|135